Oncology and Immunology Innovation Partnering on September 09-10, 2026 in Boston, United States

Advance Best- or First- in Class Candidates, Demonstrate Differentiation and Validate Technologies

Within these hyper-competitive landscapes, differentiating assets targeting proven targets, balancing efficacy with worsening toxicity, or securing minimum evidence to validate a platform are all avenues for biotech to pursue to align with pharma and investor expectations.

For biotech across ADCs, TCEs, BsAbs, TPD, and in vivo CAR-T, competing to align earlier clinical proof-of-concept data with pharma expectations, the Oncology and Immunology Innovation Partnering and Licensing Summit shares modality-specific decision-making, longer, and less competitive networking, and insights into how peers are pitching.

Ensuring relevance, favorable pharma-to-biotech ratios, and synergy across attendee interests, this high-impact forum is strategically timed between BIO and JPM as a targeted touch point.

Who Attends This Differentiated Business Development Initiative?

- Large Pharma: Heads of Business Development, Search and Evaluation, and Asset Scouting for Oncology and Immunology - comparing pipelines and enabling technologies to fuel future innovation.

- Innovative Biotech: C-level executives and BD leaders across TPD, ADCS, BsABs, TCEs, and in vivo CAR-Ts - seeking feedback, validation, and an understanding of partnership expectations with pharma and investors.

- Investors and Venture Capital: Leaders focused on disruptive investments with a higher risk appetite or looking for more validated, clinical data, looking for an opportunity to engage with peers in a relaxed environment.

Marrying collaboration across shared interests whilst delivering modality-specific depth. Pharma assesses related programs without dilution; biotech gets more efficient, higher-yielding networking.

URL:

Tickets: https://go.evvnt.com/3645023-2?pid=10008

Brochure: https://go.evvnt.com/3645023-3?pid=10008

Time: 7:00 AM - 5:00 PM

Prices:

Biotech pricing - Conference + 15 Min Presentation: USD 6498.00,

Biotech pricing - Conference Only: USD 3099.00,

Academic Pricing - Conference + 15 Min Presentation: USD 5524.00,

Academic Pricing - Conference Only: USD 2699.00

Speakers: Yue Xiong, Chief Scientific Officer, Cullgen, Yaron Sfadyah, Chief Executive Officer, Coltac Therapeutics, Xiaoqi Liu, Senior Director, Head of Business Development and Strategic Finance, Degron Therapeutics, William Ho, President, Chief Executive Officer, Director and Co-founder, IN8Bio, Weihao Xu, Founder and Chief Executive Officer, Kali Therapeutics, Reva Raghupathi, Chief Business Officer, Aarvik Therapeutics, Shawn Davis, Chief Executive Officer, Liberate Bio, Stephan Lensky, President, Chief Operating and Business Officer, Epimab Biotherapeutics, Steve Bartz, Chief Business Officer, EpiBiologics, Ugur Eskiocak, Chief Executive Officer and Co-Founder, Voro Therapeutics, Paul Moore, Chief Scientific Officer, Zymeworks, Nik Misljencevic, Director Business Development and Transactions, AbCellera, Nicki Thompson, Chief Executive Officer, Trimtech Therapeutics, Min Bao, Chief Medical Officer, Kali Therapeutics, Mike Patten, Chief Strategy Officer, Harbour BioMed, Michael Torres, Chief Executive Officer, CrossBridge Bio, Matthew Metzger, Vice President, US Operations, Oxford BioTherapeutics, Jordan Zwick, Chief Business Officer and Co-Founder, Mirador Therapeutics, John Mayfield, Chief Executive Officer, JEO Biotech Advisors, John Gerecitano, Head of Oncology Research and Development, Sana Biotechnology, John Delyani, Chief Business Officer Repertoire, Immune Medicines, Jing Li, Founder and Chief Executive Officer, VelaVigo, Jesse Chen, President and Chief Executive Officer, Fortitude Biomedicines, Jay Mei, Founder, Chairman and Chief Executive Officer, Antengene, Isabel Chiu, Senior Vice President, C4 Therapeutics, Helen Ho, Chief Business and Strategy Officer, Parabilis Medicines, Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics, Greg Dwyer, Senior Vice President, Business Development, Orum Therapeutics, Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech srl, Evan Zisholtz, Vice President, Corporate Development, Immunai, Bob Lutz, Chief Scientific Officer, Iksuda Therapeutics, Constantine Theodoropulos, Co-Founder and Chief Executive Officer, GO Therapeutics, Daniel Pereira, Chief Scientific Officer, CrossBridge Bio, David Poon, Head of Corporate Development, DCx Bio, Edouard Leroy, Co-Founder and Chief Executive Officer, Antelope Therapeutics, Arne Scheu, Co-Founder and Chief Executive Officer, Valink Therapeutics, Anna Rivkin, Chief Business Officer, Foghorn Therapeutics, Ajla Hrle, Chief Business Officer, DISCO Pharmaceuticals, Adam Gilbert, Science Partner, Flagship Pioneering, Abizer Gaslightwala, President and Chief Executive Officer, Akari Therapeutics, Xiaodong Zhang, Business Development Search and Evaluation, Oncology and Hematology, Novartis, Vikas Goyal, Partner, Growth Investments, Longwood Funds, Venkatesan Raghavan, Ph.D. Executive Director, Search and Evaluation Oncology, Novartis, Taku Fukuzawa, Principal, Chugai Pharmaceuticals, Nikhil Mutyal, Executive Director and Head of Search and Evaluation, Respiratory and Immunology, AstraZeneca, Mike Jones, Search and Evaluation Lead, GI and Inflammation, Takeda, Matthew Posluszny, Senior Director, Oncology Business Development, AstraZeneca, Kevin White, Executive Director, BI Venture Fund, Boehringer Ingelheim, Julie Di Paolo, Senior Director, Immunology Therapeutic Area Lead, Johnson and Johnson, Juanjo Cragnolini, Associate Director, Oncology Search and Evaluation, Takeda, John Flygare, Head of Large Molecule and ADC Innovation, Eli Lilly and Co., Hong Xin, Senior Director, Oncology Scientific Innovation, Johnson and Johnson, Greco Song, Investment Professional, Deep Track Capital, Dan Zheng, Head of Regional Innovation and Partnershipsm, Takeda, Daniel Abernathy, Head of Search and Evaluation, Otsuka America Pharmaceutical, Inc, Elena Diez Cecilia, Senior Director External Innovation, Johnson and Johnson, Fei Shen, Head of BD and L, USA. Global Head of Strategic Partnering, TA Inflammation, Boehringer Ingelheim, Frank Brennan, Head of Immune Reset, UCB, Christopher Tan, Executive Director BD and L, Infectious Disease, Vaccines, Oncology, Merck and Co , Carla Bauer, Director, Oncology Search and Evaluation, Business Development and Licensing, Merck and Co, Ayano Takeuchi, Scouting and Transaction Lead, IO and TPD, Astellas Innovation Management, Anu Connor, Vice President, Head of Oncology Search and Evaluation, Ipsen Pharma, Akihiro Furukawa, Director Search and Evaluation, Daiichi Sankyo